BioSpace News Archive

Spectrum Pharmaceuticals, Inc. announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Closed Loop Medicine Ltd and Pharmanovia today announced that they have entered a global co-development partnership.

CASI Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2023.

Immune IQ, a point-of-care diagnostic platform company, has been selected by the American Thoracic Society (ATS) to showcase its Immune Reveal™ platform at the 2023 Respiratory Innovation Summit.

Immutep Limited today announces that efti, a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) achieved robust initial Overall Survival (OS) in 1st line non-small cell lung cancer (1L NSCLC) patients in the Phase II TACTI-002 trial.

IN8bio, Inc. today announced positive preclinical data underscoring the potential of its DeltEx Gamma-Delta T cells to target and kill ovarian cancer.

Avenge Bio, Inc. today announced participation in the upcoming scientific and investor conferences.

ImmunoBrain Checkpoint Inc. today announced that it has dosed the first two patients in the Phase 1b IBC-01-01 clinical trial investigating IBC’s lead program, IBC-Ab002 for patients with early Alzheimer’s disease.

Lumen Bioscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for LMN-201, an investigational, orally delivered biologic drug to treat and prevent C. difficile infection (CDI).

AllianceRx Walgreens Pharmacy, one of the largest specialty and home delivery pharmacies in the U.S., will now distribute two medications indicated for adults with certain types of lymphoma.